Home  |  Contact

Cellosaurus MDA-MB-231 shWDR12-4 (CVCL_YJ26)

[Text version]

Cell line name MDA-MB-231 shWDR12-4
Accession CVCL_YJ26
Resource Identification Initiative To cite this cell line use: MDA-MB-231 shWDR12-4 (RRID:CVCL_YJ26)
Comments Group: Triple negative breast cancer (TNBC) cell line.
Doubling time: 20-27 hours (CelloPub=CLPUB00550).
Knockout cell: Method=shRNA knockdown; HGNC; 14098; WDR12.
Miscellaneous: Corrections of STR profile from thesis manuscript (CelloPub=CLPUB00550) from personal communication of Al-Awar R.
Sequence variations Heterozygous for BRAF p.Gly464Val (c.1391G>T) (ClinVar=VCV000040364) (from parent cell line).
Homozygous for CDKN2A deletion (from parent cell line).
Heterozygous for KRAS p.Gly13Asp (c.38G>A) (ClinVar=VCV000012580) (from parent cell line).
TERT c.228C>T (-124C>T); in promoter (from parent cell line).
Homozygous for TP53 p.Arg280Lys (c.839G>A) (ClinVar=VCV000376657) (from parent cell line).
Disease Breast adenocarcinoma (NCIt: C5214)
Derived from metastatic site: Pleural effusion.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0062 (MDA-MB-231)
Sex of cell Female
Age at sampling 51Y
Category Cancer cell line
STR profile Source(s): CelloPub=CLPUB00550; Direct_author_submission

Markers:
AmelogeninX
CSF1PO12,13
D5S81812
D7S8208,9
D13S31713
D16S53912
D21S1130,33.2
TH017,9.3
TPOX8,9
vWA15,18

Run an STR similarity search on this cell line
Publications

CLPUB00550
Benhamron S.
Validating WDR12 as a potential drug target in triple negative breast cancer.
Thesis MSc (2019), University of Toronto, Canada

Cross-references
Other Wikidata; Q95987355
Entry history
Entry creation19-Dec-2019
Last entry update02-Jul-2020
Version number3